Y-mAbs Therapeutics

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Price Action

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

COGT

NPCE

SLRN

THRD

TKNO

TSLA

YMAB

Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

hans-reniers-lQGJCMY5qcM-unsplash (2)

Biotech

General

Y-mAbs&#39; Omburtamab Failure: The Critical Turning Point And $19.65M Shareholder Settlement

Stein,,Switzerland,-,February,18,,2020:,Novartis,Is,The,Second

Analyst Color

Equities

Large Cap

Health Care

Analyst Ratings

ABBV

AMGN

BIIB

CATX

INCY

KYMR

REGN

Novartis aims to enhance Pluvicto&#39;s market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

Y-mAbs Therapeutics Inc

WeRide Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) announced the first European fully autonomous&nbsp;commercial <a target="_blank" href="https://www.benzinga.com//node/44030953" rel="noreferrer noopener">deployment of its Robobus</a> as part of a shuttle service collaboration with beti, Renault Group, and Macif.
This initiative brings an L4-level automated mobility solution to the Drôme area in France. The shuttle service will operate on open roads alongside mixed traffic, offering adaptable and eco-friendly transportation alternatives.
The Robobus will operate on a 3.3-kilometer route, with stops at the Valence TGV station, long-term parking, a business park's catering hub, and a group of 150 companies.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/02/44018649/spacex-rocket-launches-intuitive-machines-athena-lander-details" rel="noreferrer noopener">SpaceX Rocket Launches Intuitive Machines&#8217; Athena Lander: Details</a>
&#8220;Our collaboration with beti allows us to execute our inaugural commercial Robobus deployment in Europe, utilizing our proven track record in the Chinese, Singaporean, and Middle Eastern markets, and ultimately reinforcing our position as a global leader in L4 autonomous driving deployment and commercialization,&#8221; said CFO and Head of International Business, Jennifer Li.
Beginning March 10, Beti Automated Mobility will launch the service with a fleet of six-meter-long Robobuses, each capable of carrying up to eight passengers.
Benjamin Beaudet, CEO of beti, emphasized that the company's "hypervision" solution will add an additional layer of safety, ensuring continuous enhancements to the automated driving technology.
The trial period will run from March 10 to April 19, operating under real passenger transport conditions. This phase aims to test the technology&#8217;s efficiency and safety, before the service fully launches in July.
The service will serve several key functions, such as connecting the train station with nearby companies, providing a low-carbon transport alternative, and facilitating connections between employees and the business park's catering hub.
Price Action: WRD shares are trading lower by 4.08% at $19.01 in premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44001522/beyond-meat-slashes-jobs-and-suspends-china-operations-amid-mixed-q4-results-stock-falls" target="_blank" rel="noreferrer noopener">Beyond Meat Slashes Jobs And Suspends China Operations Amid Mixed Q4 Results; Stock Falls</a></li>
</ul>
Source: WeRide Inc.

WeRide's Robobus Rolls Out In France With Renault & Beti Backing: Details

WIIM

EXFY

Expensify shares are trading higher after the company reported better-than-expected Q4 financial results.

ANIP

ANI Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

SMCI

Super Micro Computer shares are trading lower on continued volatility following the company's quarterly report filing.

Eventbrite shares are trading lower after the company reported a Q4 EPS miss and issued FY25 sales guidance below estimates.

BTAI

BioXcel Therapeutics shares are trading higher after the company announced it regained Nasdaq listing compliance.

Piper Sandler analyst Alexander Goldfarb maintains Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) with a Underweight and lowers the price target from $17 to $16.

Price Target

Piper Sandler Maintains Underweight on Macerich, Lowers Price Target to $16

New Jersey is taking a major step forward in its cannabis industry with the official launch of its consumption lounge licensing process. The state's Cannabis Regulatory Commission (CRC) began accepting applications for on-site consumption areas on January 2, 2025, allowing businesses to create designated spaces where customers can legally use cannabis products. 
This move comes as New Jersey's legal cannabis market surpasses $1 billion in sales, according to the CRC's latest market report. The timing of this regulatory shift aligns with the upcoming <a href="https://cannabismarketspotlight.com/new-jersey/">Benzinga Cannabis Market Spotlight: New Jersey</a> event on March 4, 2025, in Somerset. At this event, industry leaders, regulators, and investors will discuss the future of New Jersey's cannabis economy, including the role of consumption lounges.
<h2 class="wp-block-heading">New Regulations and Application Timeline</h2>
According to the New Jersey Cannabis Regulatory Commission, the licensing process for consumption lounges will roll out in three phases:
<ul>
<li>January 2, 2025: Applications opened for social equity businesses, meaning those owned by individuals with past cannabis-related convictions or from economically disadvantaged communities.</li>
<li>April 2, 2025: Microbusinesses and diversely-owned dispensaries, including those owned by minorities, women, and disabled veterans, will be able to apply.</li>
<li>July 2, 2025: The process will open to all other licensed cannabis retailers.</li>
</ul>
The CRC has not set a statewide cap on the number of lounges, though each dispensary company may operate only one consumption area, regardless of how many retail locations they own. Municipal approval is required before an application can move forward, meaning local governments will play a key role in determining where lounges can open.
<h2 class="wp-block-heading">Opportunities And Challenges For Businesses</h2>
The move to allow cannabis lounges has been met with enthusiasm from business owners and consumers. According to NJ.com, many dispensaries had been waiting for months to launch lounges, as current regulations prohibit cannabis consumption in public spaces and most residential leases restrict use. These new venues are expected to provide safe, legal environments for consumers without private options.
Some businesses are already preparing for the shift. Green Market Report notes that Hashstoria, a Newark dispensary co-founded by Raekwon of the Wu-Tang Clan, has indicated plans to transition into a consumption lounge once permitted. Atlantic City has actively encouraged cannabis-related tourism and has also seen growing interest from dispensary operators looking to open lounges.
Despite the opportunities, there are regulatory hurdles. The CRC has prohibited the sale of food, alcohol, and tobacco within lounges, though customers may bring their non-alcoholic beverages. Lounges must also comply with strict ventilation and security requirements outlined in New Jersey's Smoke-Free Air Act.
<h2 class="wp-block-heading">Benzinga Cannabis Market Spotlight to Address Market Growth</h2>
With New Jersey's legal cannabis sales exceeding $1 billion in 2024, the market is expanding quickly, and industry leaders are preparing for the next development phase. The <a href="https://cannabismarketspotlight.com/new-jersey/">Benzinga Cannabis Market Spotlight: New Jersey </a>event on March 4, 2025, will bring together regulators, operators, and investors to discuss what's next for the industry.
The event will feature New Jersey Cannabis Regulatory Commission chair Dianna Houenou and acting executive director Christopher Riggs, who are expected to address how the state plans to implement and enforce on-site consumption rules. Panels will also cover investment trends, retail expansion and regulatory challenges for businesses looking to scale.
Industry experts at the event will also examine how cannabis lounges could reshape New Jersey's consumer market, particularly in cities like Jersey City and Atlantic City, where local officials have expressed interest in supporting these businesses.
<h2 class="wp-block-heading">A Defining Year for New Jersey's Cannabis Industry</h2>
New Jersey continues to refine its cannabis regulations while balancing market demand and compliance requirements. The introduction of consumption lounges marks a new phase of industry growth, allowing businesses to expand their offerings while creating safer, regulated spaces for consumers.
As the state begins licensing, local governments, business owners, and industry stakeholders will closely watch how these lounges integrate into New Jersey's broader cannabis economy. The Benzinga Cannabis Market Spotlight will be a timely forum to discuss these developments, providing insight into how New Jersey's cannabis market will evolve in 2025 and beyond.

Cannabis

Events

New Jersey Opens Door To Cannabis Lounges, Setting Stage For Industry Expansion

A $400 million opportunity over the next 4 years for electrification of over 5,000 fleet vehicles and supporting infrastructure throughout the state
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnuvve.com&amp;esheet=54216767&amp;newsitemid=20250228559856&amp;lan=en-US&amp;anchor=Nuvve+Holding+Corp.+%28NASDAQ%3A+NVVE%29%2C&amp;index=1&amp;md5=827cdb1c0b4d38321df33eb44189ba00">Nuvve Holding Corp. (NASDAQ:</a><a href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>), a global leader in grid modernization and vehicle-to-grid (V2G) technology, announced on Tuesday, Feb. 25, 2025 it was awarded a contract from the State of New Mexico (SONM), a $400 million1 opportunity over the next 4 years, to provide a comprehensive, turnkey electrification solution to support New Mexico's ambitious zero-emission vehicle (ZEV) adoption and renewable energy goals. This contract is based on Nuvve's December 2024 submittal to the SONM's "Electrify New Mexico" Request for Proposal (RFP). The SONM has awarded no other contracts to respondents of its "Electrify New Mexico" RFP.
The Nuvve contract will address the SONM's fleet electrification and supporting infrastructure. This includes $150 million to support the electrification of the SONM's school bus fleet of over 2,000 buses and $250 million to support the electrification of the SONM's transit and white fleets of over 3,500 state-owned vehicles across New Mexico.

Contracts

NVVE

Nuvve Awarded $400M Contract For New Mexico's ZEV And Renewable Energy Goals

Piper Sandler analyst Alexander Goldfarb maintains SITE Centers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) with a Overweight and lowers the price target from $20 to $19.

SITC

Piper Sandler Maintains Overweight on SITE Centers, Lowers Price Target to $19

TMCI

Treace Medical Concepts shares are trading higher after the company reported better-than-expected Q4 financial results.

Management

CBUS

Cibus President And COO Appointed As Interim CEO; Succeeds Rory Riggs

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $30 price target.

IBRX

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

Nexalin Technology To Begin Patient Recruitment For UCSD's TBI & PTSD Clinical Study

Financing

TRIB

Trinity Biotech Announces Additional $4M Funding

BFLY

Butterfly Network shares are trading lower. The company reported Q4 financial results.

ADGM

Adagio Medical Announces Strategic Restructuring To Accelerate IDE Trial And Product Innovation

Macro Economic Events

Econ #s

Economics

USA Personal Spending (MoM) For January -0.2% Vs 0.2% Est.; 0.8% Prior

USA PCE Price Index (YoY) For January 2.5% Vs 2.5% Est.; 2.6% Prior

PCE price index (MoM) (Jan) +0.3% vs +0.3% Est.; Prior +0.3%

Press Releases

Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

Clear Street Launches Healthcare & Biotechnology Equity Research

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Y-mAbs Provides Strategic Business Update and 2025 Priorities

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

CGEM

CRGX

DCTH

ELVN

ERAS

IMTX

IPSC

JANX

MLTX

NUVB

PTGX

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Y-mAbs Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga